Lancet article details ‘highly immunogenic’ performance of new vaccine
An article in the UK medical journal The Lancet details the results and testing process of a ‘highly immunogenic’ coronavirus vaccine developed in Russia.
The vaccine was trialled in two formulations, both frozen and ‘lyophilised’, with the latter being suitable for transport to hard-to-reach regions – and both performed well, giving higher levels of immunity than injecting the plasma of patients who have recovered from the virus, which up to now has been the most effective treatment available. The trials also revealed no serious adverse reactions.
The report concludes:
In conclusion, these data collectively show that the heterologous vaccine based on rAd26-S and rAd5-S is safe, well tolerated, and does not cause serious adverse events in healthy adult volunteers. The vaccine is highly immunogenic and induces strong humoral and cellular immune responses in 100% of healthy adult volunteers, with antibody titres in vaccinated participants higher than those in convalescent plasma.
Perhaps unsurprisingly, given the Tories’ boasts about (yet again) world-beating UK performance in developing treatments, the news has received little attention from the UK’s ‘mainstream’ media, with brief mentions by the BBC website and the Daily Mail about the extent of coverage.
The SKWAWKBOX is provided free of charge but depends on the support of its readers to be viable. If you can afford to, please click here to arrange a one-off or modest monthly donation via PayPal or here to set up a monthly donation via GoCardless (SKWAWKBOX will contact you to confirm the GoCardless amount). Thanks for your solidarity so SKWAWKBOX can keep bringing you information the Establishment would prefer you not to know about.
If you wish to republish this post for non-commercial use, you are welcome to do so – see here for more.